Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults".
作者信息
Boettcher Michael, Becker Corina
机构信息
Clinical Pharmacology, Bayer AG, Research & Development, Building 0520, 42096, Wuppertal, Germany.
出版信息
Clin Pharmacokinet. 2023 Nov;62(11):1651-1653. doi: 10.1007/s40262-023-01304-9. Epub 2023 Sep 26.
Abstract
摘要
相似文献
1
Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults".作者对加尼吉等人的回复：“关于‘西地那非对维立西呱在健康成年人中的安全性、耐受性、药代动力学和药效学影响的评估’的评论”
Clin Pharmacokinet. 2023 Nov;62(11):1651-1653. doi: 10.1007/s40262-023-01304-9. Epub 2023 Sep 26.
2
Comment on: Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.关于《西地那非对健康成年人中维立西呱安全性、耐受性、药代动力学和药效学影响的评价》的评论
Clin Pharmacokinet. 2023 Nov;62(11):1649-1650. doi: 10.1007/s40262-023-01303-w. Epub 2023 Sep 26.
3
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.评估西地那非对健康成年人维立西呱安全性、耐受性、药代动力学和药效学的影响。
Clin Pharmacokinet. 2023 Feb;62(2):321-333. doi: 10.1007/s40262-022-01203-5. Epub 2023 Feb 2.
4
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.维立西呱在射血分数降低的心力衰竭患者中的群体药代动力学和药效学。
Clin Pharmacokinet. 2021 Nov;60(11):1407-1421. doi: 10.1007/s40262-021-01024-y. Epub 2021 Jun 4.
5
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.维立西呱的安全性、药效学和药代动力学特征：来自六项健康受试者 I 期研究的结果。
Eur J Clin Pharmacol. 2021 Apr;77(4):527-537. doi: 10.1007/s00228-020-03023-7. Epub 2020 Oct 30.
6
Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.
N Engl J Med. 2020 Oct 8;383(15):1497-1498. doi: 10.1056/NEJMc2027731.
7
Reply: Optimal Positioning of Novel Heart Failure Pharmacotherapies: The Case of Vericiguat.回复：新型心力衰竭药物疗法的最佳定位：维立西呱的案例
JACC Heart Fail. 2021 May;9(5):403. doi: 10.1016/j.jchf.2021.03.001.
8
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply.维立西呱在射血分数降低的心力衰竭中的作用：不要忘记可溶性ST2。回复。
Eur J Heart Fail. 2020 Oct;22(10):1935. doi: 10.1002/ejhf.1765. Epub 2020 Feb 21.
9
Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats.维立西呱在大鼠和犬体内的药代动力学和物质平衡及在大鼠体内的分布。
Xenobiotica. 2022 May;52(5):453-462. doi: 10.1080/00498254.2022.2082899. Epub 2022 Jun 23.
10
Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.维立西呱：一种新型口服可溶性鸟苷酸环化酶刺激剂，用于心力衰竭的治疗。
Ann Pharmacother. 2022 May;56(5):600-608. doi: 10.1177/10600280211041384. Epub 2021 Aug 25.
引用本文的文献
1
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.维立西呱的临床药代动力学和药效学特征。
Clin Pharmacokinet. 2024 Jun;63(6):751-771. doi: 10.1007/s40262-024-01384-1. Epub 2024 Jun 25.
本文引用的文献
1
Comment on: Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.关于《西地那非对健康成年人中维立西呱安全性、耐受性、药代动力学和药效学影响的评价》的评论
Clin Pharmacokinet. 2023 Nov;62(11):1649-1650. doi: 10.1007/s40262-023-01303-w. Epub 2023 Sep 26.
2
Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.磷酸二酯酶 5 抑制剂与缺血性心脏病男性患者的口服硝酸酯类药物。
Curr Cardiol Rep. 2023 Jun;25(6):553-560. doi: 10.1007/s11886-023-01873-y. Epub 2023 Apr 19.
3
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults.评估西地那非对健康成年人维立西呱安全性、耐受性、药代动力学和药效学的影响。
Clin Pharmacokinet. 2023 Feb;62(2):321-333. doi: 10.1007/s40262-022-01203-5. Epub 2023 Feb 2.
4
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study.与缺血性心脏病男性患者同时使用磷酸二酯酶 5 抑制剂和口服有机硝酸盐相关的不良事件：病例交叉研究。
Ann Intern Med. 2022 Jun;175(6):774-782. doi: 10.7326/M21-3445. Epub 2022 Apr 19.
5
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
6
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
7
Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.患有勃起功能障碍同时处方磷酸二酯酶 5 抑制剂 (PDE5i) 和硝酸盐的患者心血管结局风险：一项使用美国电子健康记录数据的回顾性观察研究。
J Sex Med. 2021 Sep;18(9):1511-1523. doi: 10.1016/j.jsxm.2021.06.010. Epub 2021 Aug 11.
8
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.维立西呱治疗射血分数降低的心力衰竭患者的疗效。
N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
9
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.硝酸盐与5型磷酸二酯酶抑制剂相互作用的新视角。
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):375-386. doi: 10.1177/1074248418771896. Epub 2018 May 8.
Zotero 插件